Welcome to our dedicated page for Xeris Biopharma Holdings SEC filings (Ticker: XERS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Xeris Biopharma Holdings, Inc. filings document the company’s commercial biopharmaceutical operations, financial results and governance as a Nasdaq-listed issuer. Its Form 8-K reports furnish quarterly and annual operating results, business highlights, financial guidance and product-related updates for Recorlev®, Gvoke® and Keveyis®.
The filing record also includes disclosure of Recorlev patent litigation under the Hatch-Waxman Act, involving Orange Book-listed patents and ANDA-related challenges. Proxy materials cover board composition, executive compensation, equity awards, shareholder voting matters and governance practices, while current reports document board changes and compensatory arrangements.
Insider sale of XERS common stock reduced holdings: Director John Johnson sold 107,500 shares of Xeris Biopharma common stock on 08/13/2025 at a weighted average price of $7.3159 per share, leaving him with 833,483 shares beneficially owned. The Form 4 lists the sale as a direct disposition and notes the reported price is a weighted average reflecting multiple trades priced between $7.250 and $7.420. No derivative transactions or additional changes in indirect ownership are reported. The filing was signed by an attorney-in-fact on behalf of the reporting person.
Dawn Halkuff, a director of Xeris Biopharma Holdings, Inc. (XERS), reported a sale of 42,500 shares executed on 08/12/2025 at a weighted average price of $7.2759. The filing states the shares were sold in multiple transactions at prices ranging from $7.190 to $7.450. After the reported dispositions, the filing shows 115,000 shares beneficially owned directly.
The report also discloses an indirect holding of 5,410 shares through the Dawn Halkuff Revocable Trust U/A DTD 08/25/2017 and states the reporting person disclaims beneficial ownership of those trust shares except to the extent of a pecuniary interest. No derivative securities are reported.
Xeris Biopharma (XERS) submitted a Form 144 notice proposing the sale of 107,500 shares of common stock, with an aggregate market value of $786,451.77, to be offered through Morgan Stanley Smith Barney LLC on NASDAQ with an approximate sale date of 08/13/2025. The filing lists 161,480,367 shares outstanding and discloses three restricted-stock acquisition lots: 15,000 shares on 06/07/2023, 42,500 on 06/05/2024, and 50,000 on 06/04/2025. No securities of the issuer were reported sold in the past three months. The notice includes the standard certification that the seller does not possess undisclosed material information and references Rule 10b5-1 trading plans.
Xeris Biopharma Holdings, Inc. (XERS) submitted a Form 144 reporting a proposed sale of 42,500 common shares through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $309,225.75. The shares were acquired on 06/05/2024 by restricted stock vesting under a registered plan and the filing lists an approximate sale date of 08/12/2025.
The filing shows 161,480,367 shares outstanding, so the proposed sale is a very small portion of the company (approximately 0.026% of outstanding shares). The notice states there were no securities sold by the seller in the past three months and includes the seller's representation that they are not aware of any undisclosed material adverse information about the issuer. No earnings, financing, or management changes are disclosed in this filing.